Literature DB >> 26055363

Incomplete APOBEC3G/F Neutralization by HIV-1 Vif Mutants Facilitates the Genetic Evolution from CCR5 to CXCR4 Usage.

Claudia Alteri1, Matteo Surdo1, Maria Concetta Bellocchi1, Patrizia Saccomandi1, Fabio Continenza2, Daniele Armenia1, Lucia Parrotta3, Luca Carioti1, Giosuè Costa3, Slim Fourati4, Fabiola Di Santo1, Rossana Scutari1, Silvia Barbaliscia1, Valentina Fedele2, Stefania Carta2, Emanuela Balestra1, Stefano Alcaro3, Anne Genevieve Marcelin4, Vincent Calvez4, Francesca Ceccherini-Silberstein1, Anna Artese3, Carlo Federico Perno5, Valentina Svicher6.   

Abstract

Incomplete APOBEC3G/F neutralization by a defective HIV-1Vif protein can promote genetic diversification by inducing G-to-A mutations in the HIV-1 genome. The HIV-1 Env V3 loop, critical for coreceptor usage, contains several putative APOBEC3G/F target sites. Here, we determined if APOBEC3G/F, in the presence of Vif-defective HIV-1 virus, can induce G-to-A mutations at V3 positions critical to modulation of CXCR4 usage. Peripheral blood mononuclear cells (PBMC) and monocyte-derived macrophages (MDM) from 2 HIV-1-negative donors were infected with CCR5-using 81.A-VifWT virus (i.e., with wild-type [WT] Vif protein), 81.A-VifE45G, or 81.A-VifK22E (known to incompletely/partially neutralize APOBEC3G/F). The rate of G-toA mutations was zero or extremely low in 81.A-VifWT- and 81.A-VifE45G-infected PBMC from both donors. Conversely, G-to-A enrichment was detected in 81.A-VifK22E-infected PBMC (prevalence ranging from 2.18% at 7 days postinfection [dpi] to 3.07% at 21 dpi in donor 1 and from 10.49% at 7 dpi to 8.69% at 21 dpi in donor 2). A similar scenario was found in MDM. G-to-A mutations occurred at 8 V3 positions, resulting in nonsynonymous amino acid substitutions. Of them, G24E and E25K strongly correlated with phenotypically/genotypically defined CXCR4-using viruses (P = 0.04 and 5.5e-7, respectively) and increased the CXCR4 N-terminal binding affinity for V3 (WT, -40.1 kcal/mol; G24E, -510 kcal/mol; E25K, -522 kcal/mol). The analysis of paired V3 and Vif DNA sequences from 84 HIV-1-infected patients showed that the presence of a Vif-defective virus correlated with CXCR4 usage in proviral DNA (P = 0.04). In conclusion, incomplete APOBEC3G/F neutralization by a single Vif amino acid substitution seeds a CXCR4-using proviral reservoir. This can have implications for the success of CCR5 antagonist-based therapy, as well as for the risk of disease progression.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26055363      PMCID: PMC4505216          DOI: 10.1128/AAC.00137-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  68 in total

1.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments.

Authors:  Slim Fourati; Sidonie Lambert-Niclot; Cathia Soulie; Marc Wirden; Isabelle Malet; Marc A Valantin; Roland Tubiana; Anne Simon; Christine Katlama; Guislaine Carcelain; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  AIDS       Date:  2014-02-20       Impact factor: 4.177

3.  Role of low CD4 levels in the influence of human immunodeficiency virus type 1 envelope V1 and V2 regions on entry and spread in macrophages.

Authors:  Brandon L Walter; Kathy Wehrly; Ronald Swanstrom; Emily Platt; David Kabat; Bruce Chesebro
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 4.  HIV-1 envelope determinants for cell tropism and chemokine receptor use.

Authors:  T L Hoffman; R W Doms
Journal:  Mol Membr Biol       Date:  1999 Jan-Mar       Impact factor: 2.857

5.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

6.  A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.

Authors:  Anjie Zhen; Tao Wang; Ke Zhao; Yong Xiong; Xiao-Fang Yu
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

7.  Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.

Authors:  Eri Miyagi; Sandrine Opi; Hiroaki Takeuchi; Mohammad Khan; Ritu Goila-Gaur; Sandra Kao; Klaus Strebel
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

8.  Evolution of the HIV-1 env gene in the Rag2-/- gammaC-/- humanized mouse model.

Authors:  William L Ince; Liguo Zhang; Qi Jiang; Kathryn Arrildt; Lishan Su; Ronald Swanstrom
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

9.  Cytidine deamination induced HIV-1 drug resistance.

Authors:  Lubbertus C F Mulder; Ariana Harari; Viviana Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

10.  Automated generation of heuristics for biological sequence comparison.

Authors:  Guy St C Slater; Ewan Birney
Journal:  BMC Bioinformatics       Date:  2005-02-15       Impact factor: 3.169

View more
  6 in total

1.  Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.

Authors:  Morgan E Meissner; Nora A Willkomm; Jamie Lucas; William G Arndt; Sarah F Aitken; Emily J Julik; Sunanda Baliga; Louis M Mansky
Journal:  J Mol Biol       Date:  2021-11-10       Impact factor: 5.469

2.  Molecular Biology and Diversification of Human Retroviruses.

Authors:  Morgan E Meissner; Nathaniel Talledge; Louis M Mansky
Journal:  Front Virol       Date:  2022-06-02

Review 3.  APOBEC3G-Mediated G-to-A Hypermutation of the HIV-1 Genome: The Missing Link in Antiviral Molecular Mechanisms.

Authors:  Ayaka Okada; Yasumasa Iwatani
Journal:  Front Microbiol       Date:  2016-12-19       Impact factor: 5.640

4.  Role of co-expressed APOBEC3F and APOBEC3G in inducing HIV-1 drug resistance.

Authors:  Nazanin Mohammadzadeh; Robin P Love; Richard Gibson; Eric J Arts; Art F Y Poon; Linda Chelico
Journal:  Heliyon       Date:  2019-04-16

5.  The effect of HIV-1 Vif polymorphisms on A3G anti-viral activity in an in vivo mouse model.

Authors:  Cristhian Cadena; Spyridon Stavrou; Tomaz Manzoni; Shilpa S Iyer; Frederic Bibollet-Ruche; Weiyu Zhang; Beatrice H Hahn; Edward P Browne; Susan R Ross
Journal:  Retrovirology       Date:  2016-06-30       Impact factor: 4.602

Review 6.  Human APOBEC3 Variations and Viral Infection.

Authors:  Shiva Sadeghpour; Saeideh Khodaee; Mostafa Rahnama; Hamzeh Rahimi; Diako Ebrahimi
Journal:  Viruses       Date:  2021-07-14       Impact factor: 5.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.